May 3, 2023Open Access

Treatment decisions in VRE bacteraemia: a survey of infectious diseases pharmacists

Key Points

Key points are not available for this paper at this time.

Abstract

ID pharmacists overwhelmingly selected high-dose daptomycin for VRE BSI. There were variations in practice and response rate when selecting combination therapy, managing persistent bacteraemia, and treating patients with high daptomycin MICs or previous exposure to daptomycin.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

White et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8800a8c03fbaff8bef462 https://doi.org/https://doi.org/10.1093/jacamr/dlad063

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America2009 · 3,623 citations
2Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–20072008 · 3,759 citations
3A Pharmacokinetic-Pharmacodynamic Analysis to Dose Optimize Daptomycin in Vancomycin-Resistant <i>Enterococcus faecium</i> : Is the Answer Fixed Dosing or Lowering Breakpoints?2020 · 5 citations
4Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin2022 · 26 citations
5Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute2019 · 66 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper